Finerenone interactions
Full monograph for FinerenoneCheck it against another medicine
Medicines
205 documented
Mechanism
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amlodipine Besilate + Benazepril Hydrochloride | Major | Metabolism · Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor…2 documented mechanisms | 6 sources — open the full entry |
| Amlodipine Besilate + Olmesartan Medoxomil | Major | Metabolism · Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor…2 documented mechanisms | 6 sources — open the full entry |
| Amlodipine Besilate + Telmisartan | Major | Metabolism · Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor…2 documented mechanisms | 6 sources — open the full entry |
| Amlodipine Besilate + Valsartan | Major | Metabolism · Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor…2 documented mechanisms | 6 sources — open the full entry |
| Apalutamide | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Aprepitant | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Azilsartan Medoxomil | Major | Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor… | 3 sources — open the full entry |
| Azilsartan Medoxomil + Chlorthalidone | Major | Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor…2 documented mechanisms | 4 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by…2 documented mechanisms | 6 sources — open the full entry |
| Bosentan Monohydrate | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Candesartan Cilexetil | Major | Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor… | 3 sources — open the full entry |
| Candesartan Cilexetil + Hydrochlorothiazide | Major | Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor…2 documented mechanisms | 4 sources — open the full entry |
| Captopril | Major | Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor… | 3 sources — open the full entry |
| Carbamazepine | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Cenobamate | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Chloramphenicol (Oral) | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| CiprofloxacinbaseOphthalmic | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily…2 documented mechanisms | 6 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetate | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Copper Peptide + Procapil + Niacinamide + Biotin + L-Arginine | Major | Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor… | 3 sources — open the full entry |
| Crizotinib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Cyclosporine (Oral) | Major | Synergy | Coadministration with potassium-sparing diuretics or aldosterone receptor antagonists may potentiate the risk of hyperkalemia associated with the use of… | 4 sources — open the full entry |
| Dexamethasone | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily…2 documented mechanisms | 6 sources — open the full entry |
| Dexamethasone + Levofloxacin | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Dexamethasone + Tobramycin | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Diltiazem Hydrochloride | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Efavirenz | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Enalapril Maleate | Major | Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor… | 3 sources — open the full entry |
| Enzalutamide | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Eplerenone | Major | Synergy | The principal risk of eplerenone is hyperkalemia. Coadministration with potassium salts or potassium-sparing diuretics may increase this risk due to additive… | 2 sources — open the full entry |
| ErythromycinLotionOral | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| FluconazolebaseOphthalmic | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Fosphenytoin Sodium | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Furosemide + Spironolactone | Major | Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, angiotensin converting…2 documented mechanisms | 4 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Metabolism | Coadministration with potent or moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of finerenone, which is primarily… | 3 sources — open the full entry |
| Imatinib Mesylate | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Irbesartan | Major | Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor… | 3 sources — open the full entry |
| Irbesartan + Hydrochlorothiazide | Major | Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor…2 documented mechanisms | 4 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Ketoconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of finerenone, which is primarily metabolized by… | 3 sources — open the full entry |
| L-arginie + Proanthocyanidin + Folic Acid + Zinc | Major | Synergy | Concomitant use of other drugs that can increase serum potassium such as potassium-containing preparations, potassium-sparing diuretics, aldosterone receptor… | 3 sources — open the full entry |
Food & lifestyle
grapefruit juice
MajorMetabolism
Grapefruit juice may increase the plasma concentrations of finerenone. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.
What to do: Patients receiving finerenone therapy should be instructed to avoid consumption of grapefruit or grapefruit juice. In addition, patients should receive dietary counseling and be advised not to use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes or supplements are used concurrently, more frequent monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat. Finerenone may be taken with or without food.
3 sources
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Kerendia (finerenone)." Bayer Pharmaceutical Inc (2021):
- "Product Information. Kerendia (finerenone)." Bayer Plc (2022):
Conditions
Conditions in which Finerenone needs care, as documented in this source.
Adrenal Insufficiency
MajorThe use of finerenone is contraindicated in patients with adrenal insufficiency.
1 source
- "Product Information. Kerendia (finerenone)." Bayer Pharmaceutical Inc (2021):
Hepatic Insufficiency
MajorThe use of finerenone should be avoided in patients with severe liver impairment.
1 source
- "Product Information. Kerendia (finerenone)." Bayer Pharmaceutical Inc (2021):
Hyperkalemia
ModeratePatients with baseline serum potassium over 5.0 mEq/L should not initiate treatment with finerenone. Patients undergoing treatment should have their serum potassium regularly monitored and should have dose adjustments based on their serum potassium concentration.
1 source
- "Product Information. Kerendia (finerenone)." Bayer Pharmaceutical Inc (2021):
Therapeutic duplication
Drug classes that overlap with Finerenone, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
potassium sparing diuretics
The recommended maximum number of medicines in the 'potassium sparing diuretics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'potassium sparing diuretics' category.
Example product in the source data (US market): Rajani
potassium sparing diuretics
The recommended maximum number of medicines in the 'potassium sparing diuretics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'potassium sparing diuretics' category.
Example product in the source data (US market): Hydrochlorothiazide/triamterene
potassium sparing diuretics
The recommended maximum number of medicines in the 'potassium sparing diuretics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'potassium sparing diuretics' category.
Example product in the source data (US market): Moduretic 5-50
potassium sparing diuretics
The recommended maximum number of medicines in the 'potassium sparing diuretics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'potassium sparing diuretics' category.
Example product in the source data (US market): Drospirenone/estradiol
potassium sparing diuretics
The recommended maximum number of medicines in the 'potassium sparing diuretics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'potassium sparing diuretics' category.
Example product in the source data (US market): Hydrochlorothiazide/spironolactone
potassium sparing diuretics
The recommended maximum number of medicines in the 'potassium sparing diuretics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'potassium sparing diuretics' category.
Example product in the source data (US market): Nextstellis
potassium sparing diuretics
The recommended maximum number of medicines in the 'potassium sparing diuretics' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'potassium sparing diuretics' category.
Example product in the source data (US market): Ocella